Our partnership solutions

From rapid-response vaccines to personalized cancer therapies, RNA is transforming how medicines are designed and delivered. Yet successful RNA therapeutics require precise control over translation, cellular regulation, and stability.

Eclipsebio brings together AI-powered design, rapid RNA prototyping, and sequencing-based analytics into a single, integrated solution for RNA therapeutic development. Through tailored engagements or a complete lab-in-the-loop approach, we help developers reduce development risk, optimize RNA performance, and confidently advance programs toward the clinic.

The use of small oligonucleotides to regulate RNA levels and splicing has the potential to revolutionize the treatment of previously undruggable diseases. To be effective, oligonucleotides such as siRNAs and anti-miRs need to be designed to target accessible regions of genes. Furthermore, off-target binding frequently occurs which can reduce overall efficacy and produce side effects. We have combined our portfolio of proprietary technologies to characterize targets and provide comprehensive evaluations of off-target activity.

Effective small molecule therapeutics depend on selecting the right target and understanding how modulation impacts biology. Using sequencing-first technologies, we enable precise identification of disease-relevant RNA targets, validate mechanism of action, and detect transcriptome-wide off-target effects early. Our integrated approach provides a deeper view of target biology and therapeutic activity, helping teams make confident decisions and reduce downstream development risk.

Eclipsebio was founded to develop unique technologies that provide robust, unparalleled insights into understanding RNA activity and function. To support our academic partners and their groundbreaking discoveries, we have created a portfolio of proprietary assays that reveal different aspects of RNA biology. Learn how our solutions support investigations into multiple aspects of RNA biology, from deep-profiling of a single RNA to transcriptome-wide mapping of miRNA activity.

Artificial intelligence (AI) is becoming foundational to drug development, from fine-tuning gene editing therapies to be stable in specific cell types to designing more potent siRNAs. eVERSE provides the reproducible data needed to train accurate machine learning models for drug discovery.